DuPont de Nemours, Inc. (DD) Stock Analysis and Metrics

DuPont de Nemours

NYSE: DD

$137.70 ▲ +0.30 (+0.22%)

At close: Jul 24, 2026 · 4:03 PM UTC

Financial Ratios

Market Cap18.80 Bn

P/E-116.76

P/S2.72

Div. Yield-0.01

ROIC (Qtr)0.00

Total Debt (Qtr)3.17 Bn

Revenue Growth (1y) (Qtr)4.28

Add ratio to table…

About

DuPont de Nemours, Inc. is a leading provider of advanced solutions that improve everyday life across healthcare, water, construction, and industrial markets. The company focuses on helping customers advance their technology pipelines by delivering innovations in areas such as medical packaging, water purification, building technologies, and industrial adhesives. Its products support essential applications ranging from clean water access to high-performance medical devices and durable construction materials.

DuPont generates revenue primarily through the sale of high-performance materials, components, and integrated solutions to customers in regulated and mission-critical industries. The company's offerings include specialty components for medical devices, water filtration systems, construction wraps and insulations, and adhesive and lubrication products for automotive and aerospace applications. Revenue is derived from global sales to industrial manufacturers, healthcare providers, and construction firms seeking durable, efficient, and compliant technologies.

The company operates through the following segments: Healthcare & Water Technologies and Diversified Industrials.

• Healthcare & Water Technologies: This segment provides high-performance packaging, parts, and components for medical device and biopharma markets, as well as water filtration and purification technologies for industrial wastewater, energy, municipal drinking water, desalination, and life sciences applications. Key products include TYVEK® medical packaging and garments, TYCHEM® protective suits, AMBERLITE™ ion exchange resins, FILMTEC™ reverse osmosis and nanofiltration elements, and INGE™ and ITEGRATEC™ ultrafiltration modules. The segment also includes acquired businesses such as Spectrum Plastics Group, Donatelle Plastics, and Sinochem (Ningbo) RO Memtech Co., Ltd., which enhance its capabilities in specialty medical devices and reverse osmosis manufacturing.

• Diversified Industrials: This segment delivers engineered products and integrated solutions that enhance safety, performance, durability, and operational efficiency across construction and industrial end markets, including aerospace, automotive, electric vehicles, and broader industrial applications. It consists of Building Technologies, which offers solutions like TYVEK® house wrap, STYROFOAM™ insulation, and CORIAN® solid surface for new-build and repair/remodel construction, and Industrial Technologies, which supplies precision-engineered components, Vespel® shapes and parts, MOLYKOTE® specialty lubricants, BETAFORCE™ and BETASEAL™ structural adhesives, and Cyrel® flexographic printing plates. These products serve OEMs and industrial users in demanding production environments where reliability and efficiency are critical.

DuPont holds a strong competitive position in its markets due to its proprietary technologies, well-known brands, deep application expertise, and global manufacturing footprint. The company differentiates itself through innovation-driven product development, sustainability-focused solutions, and long-standing customer relationships in regulated industries. Its ability to integrate materials science with application-specific engineering allows it to address complex challenges in healthcare, water treatment, and industrial performance where few competitors offer comparable breadth and depth.

DuPont serves a diverse global customer base that includes medical device manufacturers, biopharma companies, water treatment facilities, municipal utilities, construction firms, automotive and aerospace original equipment manufacturers, and industrial producers. Specific customer types include hospitals requiring sterile packaging, cities implementing desalination plants, builders using energy-efficient wraps and insulations, and manufacturers relying on high-performance adhesives and lubricants for assembly lines and machinery.

Investment Thesis

▲ Bull case

DuPont's strategic divestiture of the Aramids business generated $1.2 billion in gross proceeds, enabling immediate capital deployment that enhances shareholder value beyond core operations, including a $275 million accelerated share repurchase that reduces diluted share count and supports earnings per share accretion, with remaining net proceeds providing dry powder for future accretive M&A or debt reduction in a rising rate environment, positioning the company to capitalize on market dislocations while maintaining its targeted 2x leverage ratio and financial flexibility for sustained capital returns.
The Healthcare & Water Technologies segment demonstrates resilient structural growth drivers, with high single-digit organic sales increases in medical packaging and biopharma fueled by aging population trends and healthcare access expansion, creating a durable revenue stream less sensitive to cyclical industrial downturns, and supported by innovation leadership evidenced by a 35% above-benchmark Vitality Index and new product launches like upgraded FILMTEC nanofiltration elements that address municipal water efficiency needs, reinforcing long-term demand in essential infrastructure markets.
Operational excellence initiatives, particularly the 80/20 margin optimization project in Diversified Industrials and widespread Kaizen activities, are delivering sustainable productivity gains with 70 basis points of net productivity improvement contributing to Q1 margin expansion, and management's focus on data-enabled tools, AI collaboration for product development, and maintenance reliability programs is building systemic resilience that converts operational variability into predictable cost and throughput benefits, supporting margin expansion guidance of 40 basis points incrementally in the first half and continued progress toward 3-year targets despite near-term headwinds.
The Middle East input cost inflation of $90 million is being fully offset through preemptive pricing actions and surcharges already embedded in guidance, with management confirming that cost recovery will be fully reflected in the second half due to timing of price increases, indicating that current margin pressure is transitory and that full-year 2026 guidance already assumes continuation of these challenges through year-end without improvement, removing uncertainty about incremental cost absorption and validating the credibility of the 4% organic growth forecast inclusive of 1% from pricing actions.
DuPont's refreshed 2035 sustainability goals and recognition as co-winner of the 2026 Innovation Excellence Award for Outstanding Innovative Culture validate its long-term strategy of embedding sustainability into business operations, driving growth through innovation and operational excellence while appealing to ESG-conscious investors and customers, with tangible outcomes like the Minimal Liquid Discharge portfolio and DESAL4ALL consortium's advancement in the XPRIZE Water Scarcity competition showcasing real-world impact in water treatment and desalination that aligns with global megatrends in resource efficiency and climate resilience.

DuPont's strategic divestiture of the Aramids business generated $1.2 billion in gross proceeds, enabling immediate capital deployment that enhances shareholder value beyond core operations, including a $275 million accelerated share repurchase that reduces diluted share count and supports earnings per share accretion, with remaining net proceeds providing dry powder for future accretive M&A or debt reduction in a rising rate environment, positioning the company to capitalize on market dislocations while maintaining its targeted 2x leverage ratio and financial flexibility for sustained capital returns.
The Healthcare & Water Technologies segment demonstrates resilient structural growth drivers, with high single-digit organic sales increases in medical packaging and biopharma fueled by aging population trends and healthcare access expansion, creating a durable revenue stream less sensitive to cyclical industrial downturns, and supported by innovation leadership evidenced by a 35% above-benchmark Vitality Index and new product launches like upgraded FILMTEC nanofiltration elements that address municipal water efficiency needs, reinforcing long-term demand in essential infrastructure markets.
Operational excellence initiatives, particularly the 80/20 margin optimization project in Diversified Industrials and widespread Kaizen activities, are delivering sustainable productivity gains with 70 basis points of net productivity improvement contributing to Q1 margin expansion, and management's focus on data-enabled tools, AI collaboration for product development, and maintenance reliability programs is building systemic resilience that converts operational variability into predictable cost and throughput benefits, supporting margin expansion guidance of 40 basis points incrementally in the first half and continued progress toward 3-year targets despite near-term headwinds.
The Middle East input cost inflation of $90 million is being fully offset through preemptive pricing actions and surcharges already embedded in guidance, with management confirming that cost recovery will be fully reflected in the second half due to timing of price increases, indicating that current margin pressure is transitory and that full-year 2026 guidance already assumes continuation of these challenges through year-end without improvement, removing uncertainty about incremental cost absorption and validating the credibility of the 4% organic growth forecast inclusive of 1% from pricing actions.
DuPont's refreshed 2035 sustainability goals and recognition as co-winner of the 2026 Innovation Excellence Award for Outstanding Innovative Culture validate its long-term strategy of embedding sustainability into business operations, driving growth through innovation and operational excellence while appealing to ESG-conscious investors and customers, with tangible outcomes like the Minimal Liquid Discharge portfolio and DESAL4ALL consortium's advancement in the XPRIZE Water Scarcity competition showcasing real-world impact in water treatment and desalination that aligns with global megatrends in resource efficiency and climate resilience.

▼ Bear case

DuPont's full-year 2026 guidance assumes the Middle East conflict continues at current intensity through year-end with no improvement baked in, yet the company only allocates 1% of its 4% organic growth forecast to pricing actions designed to offset $90 million in higher input costs, implying that the remaining 3% must come from volume growth in segments facing persistent headwinds, including flat organic sales in Diversified Industrials due to construction weakness and mixed trends in printing and packaging, raising doubts about the achievability of volume-driven growth without meaningful recovery in cyclical end markets.
Despite strong Q1 operating EBITDA margin expansion of 230 basis points year-over-year, management acknowledged sequential margin headwinds of 30 basis points from input cost timing and 40 basis points from mix in Q2, with CFO Franzen stating that these factors will reduce operating margins sequentially, indicating that the impressive Q1 margin performance may not be sustainable and that full-year guidance already factors in this degradation, suggesting the market may be overestimating the durability of current profitability levels amid ongoing cost inflation pressures.
The $275 million accelerated share repurchase, while returning capital to shareholders, represents a significant deployment of Aramids divestiture proceeds that could alternatively be used for strategic acquisitions to strengthen the portfolio mix toward higher-growth Healthcare & Water, especially given management's stated goal of shifting to a 2/3 growth mix in that segment over the medium term, and the current focus on buybacks may signal a lack of compelling internal investment opportunities or M&A targets at acceptable valuations, potentially limiting long-term transformation potential.
Although DuPont highlights innovation leadership with a 35% above-benchmark Vitality Index and new product launches, the company provides no granular data on the commercialization success or revenue contribution of these innovations, particularly in high-potential areas like microelectronics within water (20% of ion exchange) or biopharma, leaving uncertainty about whether R&D efforts are translating into meaningful top-line growth or merely maintaining existing market share in competitive segments where customers may be shifting to alternative suppliers or technologies.
The outdoor recreation industry, which DuPont indirectly supports through materials supplied to companies like REI and Patagonia, has experienced a 6% contraction between 2022 and 2025 per GlobalData, driven by slowed discretionary spending and post-pandemic inventory correction, suggesting that even if national park visitation increases due to the 250th birthday initiatives, downstream demand for gear and materials may remain subdued due to broader consumer caution, potentially limiting upside from the otherwise positive tailwind of increased outdoor activity and park funding debates.

DuPont's full-year 2026 guidance assumes the Middle East conflict continues at current intensity through year-end with no improvement baked in, yet the company only allocates 1% of its 4% organic growth forecast to pricing actions designed to offset $90 million in higher input costs, implying that the remaining 3% must come from volume growth in segments facing persistent headwinds, including flat organic sales in Diversified Industrials due to construction weakness and mixed trends in printing and packaging, raising doubts about the achievability of volume-driven growth without meaningful recovery in cyclical end markets.
Despite strong Q1 operating EBITDA margin expansion of 230 basis points year-over-year, management acknowledged sequential margin headwinds of 30 basis points from input cost timing and 40 basis points from mix in Q2, with CFO Franzen stating that these factors will reduce operating margins sequentially, indicating that the impressive Q1 margin performance may not be sustainable and that full-year guidance already factors in this degradation, suggesting the market may be overestimating the durability of current profitability levels amid ongoing cost inflation pressures.
The $275 million accelerated share repurchase, while returning capital to shareholders, represents a significant deployment of Aramids divestiture proceeds that could alternatively be used for strategic acquisitions to strengthen the portfolio mix toward higher-growth Healthcare & Water, especially given management's stated goal of shifting to a 2/3 growth mix in that segment over the medium term, and the current focus on buybacks may signal a lack of compelling internal investment opportunities or M&A targets at acceptable valuations, potentially limiting long-term transformation potential.
Although DuPont highlights innovation leadership with a 35% above-benchmark Vitality Index and new product launches, the company provides no granular data on the commercialization success or revenue contribution of these innovations, particularly in high-potential areas like microelectronics within water (20% of ion exchange) or biopharma, leaving uncertainty about whether R&D efforts are translating into meaningful top-line growth or merely maintaining existing market share in competitive segments where customers may be shifting to alternative suppliers or technologies.
The outdoor recreation industry, which DuPont indirectly supports through materials supplied to companies like REI and Patagonia, has experienced a 6% contraction between 2022 and 2025 per GlobalData, driven by slowed discretionary spending and post-pandemic inventory correction, suggesting that even if national park visitation increases due to the 250th birthday initiatives, downstream demand for gear and materials may remain subdued due to broader consumer caution, potentially limiting upside from the otherwise positive tailwind of increased outdoor activity and park funding debates.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Specialty Chemicals

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	LIN	Linde Plc	237.95 Bn	33.52	6.87	24.68 Bn
2	SHW	Sherwin Williams Co	78.17 Bn	30.07	3.27	11.70 Bn
3	ECL	Ecolab Inc.	76.02 Bn	30.01	4.73	8.24 Bn
4	APD	Air Products & Chemicals, Inc.	66.38 Bn	47.14	5.33	17.40 Bn
5	PPG	Ppg Industries Inc	26.02 Bn	3,717.41	1.61	7.83 Bn
6	LYB	LyondellBasell Industries N.V.	22.51 Bn	-28.53	0.76	11.45 Bn
7	SQM	Chemical & Mining Co Of Chile Inc	19.70 Bn	21.77	3.72	4.79 Bn
8	IFF	International Flavors & Fragrances Inc	19.51 Bn	-102.16	1.81	5.82 Bn

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password